187 related articles for article (PubMed ID: 31540607)
1. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
Evans EA; Yoo C; Huang D; Saxon AJ; Hser YI
J Subst Abuse Treat; 2019 Nov; 106():19-28. PubMed ID: 31540607
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
3. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI
J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695
[TBL] [Abstract][Full Text] [Related]
4. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
5. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
Klein MR; Darnall BD; You DS
JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
[TBL] [Abstract][Full Text] [Related]
7. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
9. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
Wong JSH; Nikoo M; Westenberg JN; Suen JG; Wong JYC; Krausz RM; Schütz CG; Vogel M; Sidhu JA; Moe J; Arishenkoff S; Griesdale D; Mathew N; Azar P
Addict Sci Clin Pract; 2021 Feb; 16(1):11. PubMed ID: 33579359
[TBL] [Abstract][Full Text] [Related]
10. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
11. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
12. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Zhu Y; Mooney LJ; Yoo C; Evans EA; Kelleghan A; Saxon AJ; Curtis ME; Hser YI
Drug Alcohol Depend; 2021 Nov; 228():108996. PubMed ID: 34555691
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
Neumann AM; Blondell RD; Hoopsick RA; Homish GG
J Addict Dis; 2020; 38(1):33-41. PubMed ID: 31774028
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
[TBL] [Abstract][Full Text] [Related]
15. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
17. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
[TBL] [Abstract][Full Text] [Related]
18. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
19. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
20. Barriers to retention in medications for opioid use disorder treatment in real-world practice.
Villamil VI; Underwood N; Cremer LJ; Rooks-Peck CR; Jiang X; Guy GP
J Subst Use Addict Treat; 2024 May; 160():209310. PubMed ID: 38331319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
